In recent years, the treatment of pulmonary arterial hypertension (PAH) has gradually increased, including new drugs and surgical methods, the mortality rate of PAH patients has significantly decreased, and the average survival rate has significantly improved. However, there was no obvious improvement in sexual health, mental health, and quality of life (QoL) in patients with PAH. Although an important dimension of QoL, little is known about sexual health and sexual health‐related QoL of patients with PAH in China. In this study, the female sexual function index (FSFI) scale, the Symptom Checklist‐90 (SCL‐90), and emPHasis‐10 were used to evaluate PAH associated with congenital heart disease (CHD‐PAH) patients’ sexual function, mental health, and QoL. The score of sexual function in female CHD‐PAH patients ranged from 4.40 to 34.80 points, and the average score was 26.80 (19.00–27.80) points. The detection rate of sexual dysfunction was 48.30%. The FSFI score of all dimensions of the sexual dysfunction group was significantly lower than that of the nonsexual dysfunction group. In addition, the scores of SCL‐90 and emPHasis‐10 were significantly higher than that of the nonsexual dysfunction group (p < 0.01). The sexual function was negatively correlated with mental health (r = −0.58, p < 0.01) and QoL (r = −0.62, p < 0.01) in female CHD‐PAH patients. The sexual function of female patients with CHD‐PAH is not optimistic. Sexual health may impact mental health and overall QoL in female PAH patients. Reasonable intervention measures should be taken to improve their sexual health, so as to improve their overall QoL.
Pulmonary arterial hypertension (PAH) is a chronic progressive exacerbation of cardiopulmonary vascular disease. The patients' exercise endurance decreased progressively and the survival rate was low. Current basic therapy and targeted drug therapy can improve the quality of life (QoL) of PAH patients, but the long‐term efficacy and prognosis are not good. In this study, the female sexual function index (FSFI) scale, Health Promoting Life Style Profile (HPLPII), and emPHasis‐10 were used to evaluate PAH patients' sexual function, health‐promoting behaviors and QoL. Their correlation and the moderating effect of health promoting behavior were conducted. In total, 306 female patients responded. Age ranged from 18 to 69 years old and the mean age was (38.049 ± 10.686). The average score of sexual function in female PAH patients was (21.703 ± 8.947) points, and the detection rate of sexual dysfunction was 51.307%. The average score of health‐promoting behaviors and QoL was (121.915 ± 13.507) points and (17.992 ± 10.245) points respectively. QoL was significantly negatively correlated with sexual function and health‐promoting behaviors, while sexual function was significantly positively correlated with health‐promoting behaviors. The health‐promoting behaviors of female patients with PAH has a moderating effect between sexual function and QoL. The sexual function, health‐promoting behaviors and QoL of female PAH patients were all at an general level. Improving the level of health‐promoting behaviors could reduce the negative predictive effect of sexual function on QoL.